Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 13/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 12/20 | 0.49 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.43 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7843650 | 0.74 | MKNK1 (0.46) | MKNK1MKNK2MAP2K3KMT2A | |
| SCHEMBL7586432 | 0.73 | CYP11B2 (0.45) | RAD51KDR | |
| SCHEMBL27843160 | 0.72 | FNTA (0.58) | KMT2A | |
| SCHEMBL7587012 | 0.72 | MKNK1 (0.46) | MKNK1MKNK2MAP2K3RAD51KMT2A | |
| SCHEMBL7584938 | 0.72 | CYP11B2 (0.47) | MKNK1MKNK2MAP2K3RAD51 | |
| SCHEMBL30514275 | 0.70 | BCAT2 (0.67) | MKNK1MKNK2KMT2ARXFP1PKN1 | |
| SCHEMBL31227976 | 0.70 | BCAT2 (0.67) | MKNK1MKNK2KMT2ARXFP1PKN1 | |
| SCHEMBL167082 | 0.70 | BCAT2 (0.67) | MKNK1MKNK2KMT2ARXFP1PKN1 | |
| SCHEMBL7589148 | 0.70 | CYP11B2 (0.48) | MKNK1MKNK2MAP2K3RAD51RXFP1 | |
| Hydrochloric Acid SCHEMBL30165666 | 0.69 | BCAT2 (0.65) | MKNK1MKNK2KMT2ARXFP1PKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020006380-A1 | Pyrrole derivatives, their preparation and pharmaceutical compositions containing them | MIGNANI SERGE (FR) | 2002-01-17 | — | — | US | claimed |
| EP-1086100-A1 | PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2001-03-28 | — | — | EP | claimed |
| WO-1999064419-A1 | PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 1999-12-16 | — | — | WO | claimed |
| US-20020006380-A1 | Pyrrole derivatives, their preparation and pharmaceutical compositions containing them | MIGNANI SERGE (FR) | 2002-01-17 | — | — | US | disclosed |
| EP-1086100-A1 | PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064419-A1 | PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006380-A1 | Pyrrole derivatives, their preparation and pharmaceutical compositions containing them | TNF, IL2, ZC3HAV1 | MKNK1 4073/4885MKNK2 4131/4885MAP2K3 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.